Saturday 17 October 2026
Export DCOY’s income statement to Excel — free account
Decoy Therapeutics Inc
DCOY Healthcare Biotechnology
In the quarter to June 2026, revenue fell 84.6%, EPS grew 94.5% and free cash flow fell 212.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.17
0.06
−4.88%
Follow DCOY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.04 | — | — | — |
+8 more quarters Free account |
P/S ratio |
1.85 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(1.44) | — | — | — | |
P/B ratio |
0.89 | — | — | — | |
Price to Tangible BV |
0.00 | — | — | — | |
EV/Sales |
(1.93) | — | — | — | |
EV/EBITDA |
0.27 | — | — | — | |
EV/Operating CF |
0.48 | — | — | — | |
EV/FCF |
0.38 | — | — | — | |
Quick Ratio |
1.77 | 1.72 | 2.07 | 2.60 | |
Current Ratio |
1.83 | 1.84 | 2.13 | 3.28 | |
Net Debt/EBITDA |
3.47 | 3.43 | 1.19 | 5.38 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.40 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.12 | 1.30 | 0.13 | 1.89 | |
Capex/Depreciation |
(3.09) | 0.00 | (147.95) | 0.00 | |
Research and Development Expense of Revenue |
573.07% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
582.91% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | — | — | |
Graham Net Nets |
1.02 | — | — | — | |
Graham Number |
183.17 | — | — | — | |
Earnings Yield |
2,553.35% | — | — | — | |
Free Cash Flow Yield |
(272.98%) | — | — | — | |
Revenue per Share |
0.43 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.98) | (5.43) | (11.72) | (41.06) | |
Capex per Share |
(0.08) | 0.00 | (5.95) | 0.00 | |
Free Cash Flow per Share |
(5.06) | (5.43) | (17.66) | (41.06) | |
Cash per Share |
15.58 | 14.70 | 110.41 | 119.94 | |
Shareholders Equity per Share |
8.12 | 7.29 | 60.71 | 105.94 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.12 | 7.29 | 60.71 | 105.94 | |
Free Cash Flow |
(2.69) | (2.89) | (1.71) | (1.65) | |
Working Capital |
3.89 | 3.81 | 5.82 | 4.22 | |
Capital Expenditures |
(0.04) | — | (0.58) | — | |
Net Current Asset Value |
3.89 | 3.81 | 5.82 | 4.22 | |
EV/EBIT |
0.27 | — | — | — | |
Capex to Sales |
0.19 | — | 0.00 | — | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Payables |
1.40 | 1.20 | 0.94 | 0.64 | |
Average Assets |
5.20 | 5.38 | 7.04 | 4.98 | |
Average Common Equity |
1.75 | 1.97 | 3.70 | 3.59 |
Columns are period end dates